← All trials
NCT06088199
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 24, 2023
- Primary completion
- Dec 17, 2026
- Completion date
- Dec 17, 2026
- First posted
- Oct 18, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.